Indian Immunologicals opens Rs250 crore vaccine facility near Hyderabad
1 min read 26 Oct 2015, 10:34 PM ISTIIL to significantly expand its manufacturing capabilities to meet growing demand for vaccines
Premium
Hyderabad: Indian Immunologicals Ltd (IIL), a unit of the National Dairy Development Board, said on Monday that its new ₹ 250 crore facility to make human and animal vaccines near Hyderabad had begun operations.
Spread across 47 acres, the unit at Phase III of the Genome Valley complex Kakarpatla is IIL’s second manufacturing unit in Hyderabad, and will significantly expand its manufacturing capabilities to meet growing demand for vaccines.
The human vaccine facility meets the World Health Organisation’s pre-qualification standards necessary to participate in global tenders for supply of vaccines to child immunisation programmes. The company said the facility has the capacity to produce 8 million doses of human rabies vaccine a year.
“The facility will strengthen IIL’s position in the industry and will immensely increase our manufacturing capabilities," said K. Anand Kumar, deputy managing director of IIL.
